Fox Run Management L.L.C. acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,117 shares of the biotechnology company's stock, valued at approximately $328,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after purchasing an additional 80,400 shares during the period. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics in the 3rd quarter valued at about $61,858,000. Raymond James Financial Inc. bought a new position in ADMA Biologics in the 4th quarter worth about $19,076,000. EWG Elevate Inc. purchased a new position in shares of ADMA Biologics during the fourth quarter worth approximately $480,000. Finally, Citigroup Inc. increased its position in shares of ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock worth $7,741,000 after acquiring an additional 277,138 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.
Get Our Latest Stock Report on ADMA Biologics
ADMA Biologics Stock Down 0.1 %
NASDAQ ADMA traded down $0.02 during trading on Friday, reaching $20.26. 2,360,170 shares of the company's stock traded hands, compared to its average volume of 3,517,452. ADMA Biologics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market cap of $4.79 billion, a price-to-earnings ratio of 72.36 and a beta of 0.60. The company's 50 day simple moving average is $17.13 and its two-hundred day simple moving average is $18.16.
ADMA Biologics Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Stories
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
